Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258321 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations
A Phase 1 study, sponsored by Presidio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02258321: Completed Phase 1 study, sponsored by Presidio Pharmaceuticals.
NCT02258321 is a Phase 1 study that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02258321, a Phase 1 study, has completed, sponsored by Presidio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.
Interventions
- DRUG PPI-668 capsule
- DRUG PPI-668 tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
What the finished NCT02258321 record still lists
NCT02258321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which PPI-668 capsule is the first listed.
NCT02258321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02258321 about?
NCT02258321 is a clinical study titled "Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations". This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.
What is the current status of trial NCT02258321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02258321?
The interventions under investigation include: PPI-668 capsule (DRUG), PPI-668 tablet (DRUG).
Who is sponsoring clinical trial NCT02258321?
This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02258321's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia